Genotype–Phenotype Correlations, Treatment, and Prognosis of Children With Early‐Onset (Neonatal) Marfan Syndrome
Clinical Genetics · 2025
DOI: 10.1111/cge.14722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2025. Verfasst von Eva C van der Leest und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Marfan Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Steun Emma Kinderziekenhuis, Donations by the sales of the book "Een magisch getal", Dutch Ministry of Education, Culture and Science.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Early‐onset Marfan syndrome (eoMFS) is a severe and rare form of Marfan syndrome characterized by severe atrioventricular valve insufficiency developing before or shortly after birth. It is unclear which factors (interventions and/or genotype) influence survival. Forty‐one individuals with eoMFS with a fibrillin‐1 gene ( FBN1 ) variant in exon 24–32 (CRCh37) were included. At the last follow‐up, 14/41 (34%) were alive (8 months‐18 years) and 27/41 (66%) were deceased. Median age of death was 1 month and 88% of the deaths occurred before 5 months of age. More individuals alive past the age of 16 months versus those who were deceased before that age had undergone cardiovascular surgery at an older age (13 months, range 3–72, vs. 2 months, range 2–2, p = 0.03). Survival was better in those with single amino acid substitutions/small in‐frame deletions than in those with large in‐frame deletions ( p = 0.007), but variants involving a cysteine substitution in an EGF‐like domain versus those involving other amino acids did not significantly influence survival. EoMFS ranges from a (pre‐)neonatal life‐threatening disorder to a disorder with enhanced survival, creating a window for cardiovascular surgery. Individuals with single amino acid substitutions/small in‐frame deletions had better survival compared to those with variants significantly impacting exon 24–32 length.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, the Netherlands.
- Amsterdam Reproduction & Development, Amsterdam, the Netherlands.
- Department of Pediatric Cardiology, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, the Netherlands.
- Department of Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
- Rare Bone Disease Center Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Movement Sciences, Rehabilitation and Development, Amsterdam, the Netherlands.
ORCID-Profile: Jessica Warnink-Kavelaars
Förderung
- Stichting Steun Emma Kinderziekenhuis
- Donations by the sales of the book "Een magisch getal"
- Dutch Ministry of Education, Culture and Science
Zitieren
APA
van der Leest, E. C., van der Hulst, A. E., Pals, G., Zhytnik, L., Lai, L., Jacquemart, C., Mills, L., Houben, M., Jira, P., Lunshof, B. L., Warnink-Kavelaars, J., de Waard, V., & Menke, L. A. (2025). Genotype–Phenotype Correlations, Treatment, and Prognosis of Children With Early‐Onset (Neonatal) Marfan Syndrome. Clinical Genetics. https://doi.org/10.1111/cge.14722
Vancouver
van der Leest EC, van der Hulst AE, Pals G, Zhytnik L, Lai L, Jacquemart C, et al. Genotype–Phenotype Correlations, Treatment, and Prognosis of Children With Early‐Onset (Neonatal) Marfan Syndrome. Clinical Genetics. 2025. doi:10.1111/cge.14722
BibTeX
@article{vanderLeest2025,
author = {van der Leest, Eva C and van der Hulst, Annelies E and Pals, Gerard and Zhytnik, Lidiia and Lai, Lillian and Jacquemart, Caroline and Mills, Lindsay and Houben, Michiel and Jira, Petr and Lunshof, Bert L and Warnink-Kavelaars, Jessica and de Waard, Vivian and Menke, Leonie A},
title = {Genotype–Phenotype Correlations, Treatment, and Prognosis of Children With Early‐Onset (Neonatal) Marfan Syndrome},
journal = {Clinical Genetics},
year = {2025},
doi = {10.1111/cge.14722}
}
EUVIMED